ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AGL Angle Plc

10.50
-0.50 (-4.55%)
22 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -4.55% 10.50 10.00 11.00 11.00 10.50 11.00 1,004,092 14:47:52
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 2.19M -20.13M -0.0624 -1.68 35.49M
Angle Plc is listed in the Business Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 11p. Over the last year, Angle shares have traded in a share price range of 7.25p to 37.50p.

Angle currently has 322,641,668 shares in issue. The market capitalisation of Angle is £35.49 million. Angle has a price to earnings ratio (PE ratio) of -1.68.

Angle Share Discussion Threads

Showing 33051 to 33072 of 33175 messages
Chat Pages: 1327  1326  1325  1324  1323  1322  1321  1320  1319  1318  1317  1316  Older
DateSubjectAuthorDiscuss
15/11/2024
14:10
Well there should be a modicum of humility from some of the bulls here. The bearish view concerning a fundraise was actually correct and similarly with missing the revenue target.
boris cobaka
15/11/2024
13:51
Remember that loon adw? Yasx? REMEMBER THE FUD AT 7.50 BID?
atmysignal
15/11/2024
13:49
The assay identified CTCs in 91% (29/32) of metastatic lung cancer patients assessed as part of an ongoing longitudinal study, presenting with a range of phenotypes. PD-L1 positive CTCs were observed in 72% of patients with a PD-L1 positive tissue biopsy and in 27% of patients with a PD-L1 negative tissue biopsy, demonstrating the potential for improved assessment of tumour heterogeneity through analysis of PD-L1 status in CTCs.
outsizeclothes.com
15/11/2024
12:32
I am only an amateur chartist but to me it looks as though the price has finally broken above its downtrend. Any more knowledgeable chartists out there care to comment.
mesquida
15/11/2024
12:32
698 bringing out the aliases again. Sad
muffster
15/11/2024
11:20
course they are. Keep telling yerself and eventually it'll be so...

meanwhile back in the lab....

boris cobaka
15/11/2024
10:53
boris - I disagree they are not PI profit takers. The sells are coming from one source and they are selling into PI buyers on the non-RNS updates. There are thousands of methods out there to improve cancer drugs and treatments but it does not mean big pharma will adopt them all on an industrial scale. Sadly Parsortix seems to fall into this category.
pwhite73
15/11/2024
10:40
full marks for effort pwhite
boris cobaka
15/11/2024
10:39
I suspect some traders taking profits from acquiring sub 9p.
Wonder if they'll be able to buy back cheaper....

boris cobaka
15/11/2024
10:23
For crying out loud look at the reds from 10:11 - 10:14. D'you think its individual retail shareholders all deciding to sell at the same time. The sells are coming from one source and the reason why it still can't climb above the placing price of 15p because the next placing is 10p in my opinion of course.
pwhite73
15/11/2024
10:22
POLX Polarean Imaging about to break out above 2p soon. Mcap even less than AGL but cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 155p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.

Putting this UK recovery play potential on radars.

1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.

APPROX 13P SHARE PRICE EQUIVALENT FOR POLX


2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M

APPROX 48P SHARE PRICE EQUIVALENT FOR POLX


3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.

APPROX 22P SHARE PRICE EQUIVALENT FOR POLX

4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout

POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice.

m_night10
15/11/2024
09:53
From Half Year Report in September

"Prioritising investment towards growth of the large pharma strategy and reducing investment in the products side is intended to maximise ANGLE's commercial opportunity and is now anticipated to deliver cashflow positive trading in the second half of 2026; and the Company is funded to execute on this plan"

seball
15/11/2024
09:52
You're wasting your time here.
puphead
15/11/2024
09:51
Remember the ones scaring you to sell at 7.50 bid
atmysignal
15/11/2024
09:51
Pwhite yet again a contrarian investor / signal to buy
Only PATT comes close to this 100 percent track record
Quite unbelievable really

washingmachine
15/11/2024
09:48
"When AIM/small cap companies tell you they are funded until 202X it does not mean they won't be placing until after that date it means they have discussed funding with their brokers and nomads who have assured they they will be able to raise money on the capital markets up to and beyond that date"Please send me whatever youre smoking
zeus19
15/11/2024
09:43
zeus19 - "deliver cashflow positive trading in the second half of 2026; and the Company is funded to execute on this plan"

When AIM/small cap companies tell you they are funded until 202X it does not mean they won't be placing until after that date it means they have discussed funding with their brokers and nomads who have assured them they will be able to raise money on the capital markets up to and beyond that date.

pwhite73
15/11/2024
09:39
Keeps going NT on my platform.
bsg
15/11/2024
09:25
6 weeks ago, the company stated:"Prioritising investment towards growth of the large pharma strategy and reducing investment in the products side is intended to maximise ANGLE's commercial opportunity and is now anticipated to deliver cashflow positive trading in the second half of 2026; and the Company is funded to execute on this plan"Key part being "the Company is funded to execute on this plan" And youre talking about a placing...
zeus19
15/11/2024
09:09
The date is 11th September 2024 it is not new.
pwhite73
15/11/2024
08:44
seball, is this a new note, when exactly was It published ?
mesquida
15/11/2024
08:44
volume spike t'other day was not for nowt...

First nibble.
Tight lines....

boris cobaka
Chat Pages: 1327  1326  1325  1324  1323  1322  1321  1320  1319  1318  1317  1316  Older